SCHEMBL14132845

SCHEMBL14132845

COc1ccccc1C1CC(c2ccc(NS(=O)(=O)c3ccc(Cl)cc3)cc2)=NN1C(C)=O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 4/20 0.65
▸ MAOB P27338 4/20 0.65
▸ MAPT P10636 3/20 0.63
▸ ALDH1A1 P00352 1/20 0.63
▸ SMN1; SMN2 Q16637 1/20 0.63
▸ PTGS2 P35354 2/20 0.56
▸ KDM4E B2RXH2 1/20 0.56
▸ CA1 P00915 4/20 0.55
▸ CA2 P00918 4/20 0.55
▸ MEN1 O00255 2/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ NPC1 O15118 1/20 0.53
▸ RAB9A P51151 1/20 0.53
▸ CA9 Q16790 3/20 0.52
▸ CA4 P22748 1/20 0.52
▸ PPARG P37231 1/20 0.51
▸ NCOA2 Q15596 1/20 0.51
▸ NCOA1 Q15788 1/20 0.51
▸ NCOA3 Q9Y6Q9 1/20 0.51
▸ PKM P14618 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14133506 0.93 MAOB (0.70) MAOAMAOBMAPTALDH1A1SMN1; SMN2
SCHEMBL14057504 0.92 MAOA (0.66) MAOAMAOBMAPTALDH1A1SMN1; SMN2
SCHEMBL14133514 0.89 MAOB (0.66) MAOAMAOBALDH1A1PTGS2KDM4E
SCHEMBL14133296 0.87 MAPT (0.81) MAOAMAOBMAPTALDH1A1SMN1; SMN2
SCHEMBL14133755 0.85 MAOB (0.70) MAOAMAOBMAPTALDH1A1SMN1; SMN2
SCHEMBL14136236 0.85 PTGS2 (0.69) MAOAMAOBPTGS2KDM4ECA1
SCHEMBL14133511 0.85 MAOB (0.64) MAOAMAOBPTGS2CA1CA2
SCHEMBL14136252 0.84 PTGS2 (0.77) MAOAMAOBPTGS2CA1CA2
SCHEMBL14058025 0.84 NPC1 (0.78) MAOAMAOBPTGS2CA1CA2
SCHEMBL14133500 0.83 MAOB (0.69) MAOAMAOBMAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — US disclosed
WO-2012160447-A1 3, 5 -DIPHENYL- SUBSTITUTED PYRAZOLINES FOR THE TREATMENT OF CANCER, PROLIFERATIVE, INFLAMMATORY OR AUTOIMMUNE DISEASES DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — WO disclosed
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 PDK2, PDK4, PDK3 MAOA 4254/4885MAOB 4183/4885MAPT 3332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback